OSLO, Norway, April 5, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that President and Chief Executive Officer, Dan Schneider will present a corporate overview and host 1-on-1 meetings with investors at the 23rd Annual Needham Healthcare Conference being held virtually April 8-11, 2024.
OSLO, Norway, March 18, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today the Phase III clinical study results for its non-surgical treatment candidate for cervical high-grade squamous intraepithelial lesions (HSIL) Cevira® (APL-1702). The results were presented at two recent medical congresses and demonstrated highly statistically significant efficacy and a favorable safety profile for Cevira, with a significant clearance rate of high-risk HPV16 and/or HPV18 compared to placebo (p=0.0001).
OSLO, Norway, Feb. 21, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 114.2 million in the fourth quarter of 2023, an increase of 20% over the prior-year period (Q4 2022: NOK 94.9 million), and EBITDA of NOK 29.9 million (NOK -16.9 million) following solid business development for the Company. Total revenues increased 37% in the fourth quarter of 2023 compared to Q4 2022, including a milestone payment from Asieris related to the license agreement for Cevira®. Photocure has an ambition to deliver 40-70 new and upgraded Saphira™ tower installations in 2024, consolidated product revenue growth of 6% to 9% (constant currency), and positive EBITDA excluding business development expenses.
OSLO, Norway, Sept. 20, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that the multinational Cevira® Phase III clinical trial has been completed and successfully met its primary endpoint. Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure.
OSLO, Norway, Aug. 9, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 115.9 million in the second quarter of 2023 (Q2 2022: NOK 99.9 million), and an EBITDA of NOK 23.4 million (NOK 1.4 million). The Company reiterates its 2023 annual guidance of new Saphira™ blue light tower installations in the U.S. expected in the range of 65 to 75, anticipated consolidated product revenue growth above 20%, and positive EBITDA excluding business development spending.
OSLO, Norway, Feb. 20, 2023 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data from the Veterans Affairs (VA) BRAVO study at the ASCO Genitourinary Cancers Symposium (ASCO GU) which was held February 16-18, 2023 in San Francisco, USA. The clinical data demonstrated a significant decrease in the risk of recurrence & longer time to recurrence following Blue Light cystoscopy (BLC®) with Cysview® compared to White Light cystoscopy (WLC) alone.
OSLO, Norway, Dec. 5, 2022 /PRNewswire/ -- Photocure ASA, The Bladder Cancer Company, announces that new evidence was presented at the 22nd Annual Society of Urologic Oncology (SUO) Meeting demonstrating that Blue Light Cystoscopy (BLC®) decreases the risk and prolongs time to recurrence based on Real World Evidence from the U.S. multi-institutional Blue Light Cystoscopy with Cysview® Registry database.
OSLO, Norway, Sept. 28, 2022 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the commercial availability of Karl Storz's New Blue Light equipment powered by Saphira™ in the U.S. As part of the rollout, Karl Storz plans to host a Virtual Launch event for the medical community streamed from its El Segundo, California office where Sia Daneshmand M.D. and Kristin Scarpato M.D. M.P.H. will discuss the clinical benefits of using BLC® with Cysview® for NBMIC*, while sharing their perspectives on the advantages that the New Blue Light system provides over the original system for TURBT**. The Virtual Launch event is scheduled to take place on October 13, 2022 at 4:00pm Pacific Time.
OSLO, Norway, March 11, 2022 /PRNewswire/ -- Photocure ASA (PHO: OSE), The Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (688176.SH) has obtained approval to conduct a real-world evidence study for Hexvix® in Hainan, China, in addition to the Phase III study approved last month.
OSLO, Norway, Dec. 27, 2021 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner and exclusive distributor, Asieris MediTech in mainland China and Taiwan has communicated the first patient experience with Hexvix® in the Bo'ao Lecheng International Medical Tourism Pilot Zone in Hainan Province. Asieris communicated that Hexvix received its first prescription in China by Hainan General Hospital and the first patient procedure was completed on December 26.